SCHEMBL4857124

SCHEMBL4857124

Cc1cc([Si](C)(C)C)ccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 13/20 0.61
ESR2 Q92731 12/20 0.61
AR P10275 4/20 0.61
TP53 P04637 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
PDE10A Q9Y233 1/20 0.48
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42
G6PD P11413 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12339907 0.82 ESR1 (0.57) ESR1ESR2ARTP53TDP1
SCHEMBL4853969 0.81 TSHR (0.48) ESR1ESR2ARTP53TDP1
SCHEMBL18604566 0.80 TRPA1 (0.46) ESR1ESR2ARTP53TDP1
SCHEMBL3313456 0.77 ALDH1A1 (0.42) ESR1ESR2ARTDP1KDM4E
SCHEMBL13318430 0.76 ESR1 (0.36) ESR1ESR2ARTP53TDP1
SCHEMBL3824007 0.75 ALDH1A1 (0.40) ESR1ESR2ARTDP1KDM4E
SCHEMBL13086248 0.74 ALDH1A1 (0.52) ESR1ESR2ARTDP1PDE10A
SCHEMBL1920935 0.74 ACHE (0.39) ESR1ESR2ARKDM4ECYP3A4
SCHEMBL18234154 0.73 ESR1 (0.33) ESR1ESR2AR
SCHEMBL17746494 0.73 ESR1 (0.34) ESR1ESR2AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184833-A Phenolic amine type internal electron donor composition for ethylene polymerization catalyst and preparation method thereof 中国石油天然气股份有限公司 2024-06-14 CN disclosed
US-7737291-B2 2,4,6,8-tetramethylcyclotetrasiloxane and stabilizer used as a material for thin film formation by chemical vapor deposition, or atomic layer deposition ADEKA CORPORATION (JP) 2010-06-15 US disclosed
US-20080261918-A1 Silicon Compounds and Their Use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-23 US disclosed
US-7407649-B2 Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents PARADIGM THERAPEUTICS LTD (GB) 2008-08-05 US disclosed
US-7407649-B2 Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents PARADIGM THERAPEUTICS LTD (GB) 2008-08-05 US disclosed
US-20070232821-A1 Composition Containing Siloxane Compound and Phenol Compound ADEKA CORPORATION (JP) 2007-10-04 US disclosed
EP-1644385-B1 SILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-08-29 EP disclosed
EP-1644385-B1 SILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-08-29 EP disclosed
US-20070110708-A1 Silicon compounds and their use PARADIGM THERAPEUTICS LTD (GB) 2007-05-17 US disclosed
US-20070110708-A1 Silicon compounds and their use PARADIGM THERAPEUTICS LTD (GB) 2007-05-17 US disclosed
CN-1823076-A Silicon compounds and their use PARADIGM THERAPEUTICS LTD (GB) 2006-08-23 CN disclosed
EP-1644385-A1 SILICON COMPOUNDS AND THEIR USE Paradigm Therapeutics Limited (GB) 2006-04-12 EP disclosed
WO-2005005442-A1 SILICON COMPOUNDS AND THEIR USE PARADIGM THERAPEUTICS LTD. (GB) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070110708-A1 Silicon compounds and their use SOST, SMAD3, SMAD2 ESR1 533/4885ESR2 476/4885AR 1957/4885
US-20070232821-A1 Composition Containing Siloxane Compound and Phenol Compound H1-0, CYP2S1, H1-4 ESR1 46/4885ESR2 283/4885AR 110/4885
US-20080261918-A1 Silicon Compounds and Their Use SOST, SIK2, SCLY ESR1 492/4885ESR2 231/4885AR 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.